Optimizing DMD management in Asia: Current challenges and future directions.

IF 3.4 4区 医学 Q2 CLINICAL NEUROLOGY Journal of neuromuscular diseases Pub Date : 2025-01-01 DOI:10.1177/22143602241297846
Wen-Chin Weng, Sophelia H S Chan, Roy Gomez, Furene Wang, Hsu-Wen Chou, Jocelyn Lim, Sarah Tsai, Ting Rong Hsu, Yuh-Jyh Jong
{"title":"Optimizing DMD management in Asia: Current challenges and future directions.","authors":"Wen-Chin Weng, Sophelia H S Chan, Roy Gomez, Furene Wang, Hsu-Wen Chou, Jocelyn Lim, Sarah Tsai, Ting Rong Hsu, Yuh-Jyh Jong","doi":"10.1177/22143602241297846","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Since 1970, advances in Duchenne muscular dystrophy (DMD) management have significantly extended the patients' life expectancy. However, DMD remains universally fatal.</p><p><strong>Objective: </strong>To understand the current DMD management standards and practices in Asia and to evaluate inconsistencies, unmet needs, and future directions for DMD patient management in the region.</p><p><strong>Methods: </strong>Clinical experts from Hong Kong, Singapore, and Taiwan convened in September 2023 to discuss DMD diagnosis, assessment, treatment, and management best practices. A pre-meeting survey was also administered to explore professional perspectives and practices and refine the discussion focus.</p><p><strong>Results: </strong>Genetic profiling has become the pivotal diagnostic tool and has been universally adopted by experts. Steroid therapy is recognized as the cornerstone of DMD care. However, there are various opinions regarding the timing of its initiation and whether it should be continued after the loss of ambulation. Gene therapy has the potential to significantly improve outcomes in patients with DMD. However, its adoption is hampered by high costs, the potential for serious adverse events, and difficulties with patient selection. Governments and manufacturers must work together to improve its affordability. Establishing a centralized DMD registry garnered strong support from the experts as it promised to provide insights into unique DMD subtypes, standardize treatment protocols, and facilitate the conduct of clinical trials. Furthermore, the introduction of gene therapy has highlighted the need for generating long-term safety and effectiveness data in patients with DMD. Lastly, a centralized patient registry can be used to inform policy decisions.</p><p><strong>Conclusions: </strong>DMD care in Asia is characterized by substantial heterogeneity, with financial and reimbursement issues playing a major role in management decisions. A centralized patient registry has the potential to address these concerns by providing a valuable source of information.</p>","PeriodicalId":16536,"journal":{"name":"Journal of neuromuscular diseases","volume":"12 1","pages":"22143602241297846"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuromuscular diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/22143602241297846","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Since 1970, advances in Duchenne muscular dystrophy (DMD) management have significantly extended the patients' life expectancy. However, DMD remains universally fatal.

Objective: To understand the current DMD management standards and practices in Asia and to evaluate inconsistencies, unmet needs, and future directions for DMD patient management in the region.

Methods: Clinical experts from Hong Kong, Singapore, and Taiwan convened in September 2023 to discuss DMD diagnosis, assessment, treatment, and management best practices. A pre-meeting survey was also administered to explore professional perspectives and practices and refine the discussion focus.

Results: Genetic profiling has become the pivotal diagnostic tool and has been universally adopted by experts. Steroid therapy is recognized as the cornerstone of DMD care. However, there are various opinions regarding the timing of its initiation and whether it should be continued after the loss of ambulation. Gene therapy has the potential to significantly improve outcomes in patients with DMD. However, its adoption is hampered by high costs, the potential for serious adverse events, and difficulties with patient selection. Governments and manufacturers must work together to improve its affordability. Establishing a centralized DMD registry garnered strong support from the experts as it promised to provide insights into unique DMD subtypes, standardize treatment protocols, and facilitate the conduct of clinical trials. Furthermore, the introduction of gene therapy has highlighted the need for generating long-term safety and effectiveness data in patients with DMD. Lastly, a centralized patient registry can be used to inform policy decisions.

Conclusions: DMD care in Asia is characterized by substantial heterogeneity, with financial and reimbursement issues playing a major role in management decisions. A centralized patient registry has the potential to address these concerns by providing a valuable source of information.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
优化亚洲的DMD管理:当前的挑战和未来的方向。
背景:自1970年以来,杜氏肌营养不良症(DMD)治疗的进展显著延长了患者的预期寿命。然而,DMD仍然是普遍致命的。目的:了解亚洲地区目前DMD管理标准和实践,评估该地区DMD患者管理的不一致性、未满足的需求和未来发展方向。方法:来自香港、新加坡和台湾的临床专家于2023年9月召开会议,讨论DMD的诊断、评估、治疗和管理最佳实践。还进行了会前调查,以探索专业观点和实践,并细化讨论重点。结果:基因图谱已成为关键的诊断工具,并已被专家普遍采用。类固醇治疗被认为是DMD治疗的基石。然而,对于其启动的时间以及在失去行动能力后是否应该继续存在各种意见。基因治疗有可能显著改善DMD患者的预后。然而,它的采用受到高成本、潜在的严重不良事件和患者选择困难的阻碍。政府和制造商必须共同努力,提高其可负担性。建立一个集中的DMD登记处得到了专家的大力支持,因为它承诺提供对独特的DMD亚型的见解,标准化治疗方案,并促进临床试验的进行。此外,基因治疗的引入强调了对DMD患者产生长期安全性和有效性数据的需求。最后,可以使用集中的患者登记来为政策决策提供信息。结论:亚洲的DMD护理具有很大的异质性,财务和报销问题在管理决策中起着主要作用。通过提供有价值的信息来源,集中的患者登记处有可能解决这些问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of neuromuscular diseases
Journal of neuromuscular diseases Medicine-Neurology (clinical)
CiteScore
5.10
自引率
6.10%
发文量
102
期刊介绍: The Journal of Neuromuscular Diseases aims to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias and myositis). The journal publishes research reports, reviews, short communications, letters-to-the-editor, and will consider research that has negative findings. The journal is dedicated to providing an open forum for original research in basic science, translational and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases.
期刊最新文献
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study. Characteristics of muscle cramps as a prodromal symptom of sporadic amyotrophic lateral sclerosis. Neurologists' decision-making in the management of generalised myasthenia gravis: Therapeutic inertia and treatment choices. Substance use may be associated with non-adherence to non-invasive ventilation in adults with myotonic dystrophy type 1. Active-NDM: Development of a patient-reported outcome questionnaire to measure the impact of non-dystrophic myotonia on activity of daily living.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1